Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai and Biogen's Leqembi (lecanemab), which was approved by the country's ...
15d
GlobalData on MSNEisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosingThe FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...
Eisai makes it clear that the intention is in part to help support the rollout of Biogen-partnered Leqembi (lecanemab ... which was approved by Japan’s Ministry of Heath, Labour and Welfare ...
On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...
2hon MSN
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
LEQEMBI is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, Great Britain, Mexico and Macau. In November 2024, the treatment received a positive opinion from the Committee ...
Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...
LEQEMBI is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, Great Britain, Mexico and Macau. In November 2024, the treatment received a positive opinion from the Committee ...
INDICATION LEQEMBI ® [ (lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results